Gilead gets another HIV treatment approval, extending lenacapavir’s dominancenews2026-08-27T22:14:58+00:00August 27th, 2026|Endpoints News|
Roivant’s dermatomyositis drug Lisraya snags FDA approvalnews2026-08-27T21:27:19+00:00August 27th, 2026|Endpoints News|
Impacts of CMS’ GLP-1 pilot program begin to take shapenews2026-08-27T18:41:54+00:00August 27th, 2026|Endpoints News|
Pharma’s legal battle over Medicare negotiations reaches ‘dead end’news2026-08-27T17:30:58+00:00August 27th, 2026|Endpoints News|
Q&A: Akeso CEO spells out why she thinks its biliary tract cancer data are a big dealnews2026-08-27T15:45:21+00:00August 27th, 2026|Endpoints News|
Lilly’s move to hide Phase 1 pipeline draws mixed reviewsnews2026-08-27T15:02:11+00:00August 27th, 2026|Endpoints News|
Moderna’s $2B offering; AstraZeneca-Amgen and Biokin chalk up Phase 3 winsnews2026-08-27T14:59:41+00:00August 27th, 2026|Endpoints News|
Why one venture investor is going from ‘studio’ to ‘firm’news2026-08-27T14:54:25+00:00August 27th, 2026|Endpoints News|
Lonza creates commercial chief position; WuXi Biologics reports revenue jump news2026-08-27T14:31:09+00:00August 27th, 2026|Endpoints News|
Metriport raises $26M to help doctors retrieve patient datanews2026-08-27T13:00:19+00:00August 27th, 2026|Endpoints News|
